Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

Lars H Lund, Arantxa Barandiarán Aizpurua, Entela Bollano, Oscar Braun, Jan Leendert P Brouwer, Jan W Buikema, Antonio Cannata, Roy S Gardner, M Louis Handoko, Chim C Lang, Marco Metra, Gianfranco Sinagra, Tonje Thorvaldsen, Robert M A van der Boon, Bart J van Essen, Sanjiv J Shah, Adriaan A Voors, Carolyn S P Lam, Bertram Pitt, Scott D Solomon, Camilla Hage, Marcus Stahlberg, Alberto Bernareggi, Allan Gordon, Marianna Del Sole, Elin Rosendahl, Patrik Stromberg, Goran Westerberg, Robert Edfors, Mark C Petrie

Open source

DOI: 10.1016/s0140-6736(26)00904-9
Published: 2026-07
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00904-9,
  title = {Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study},
  author = {Lars H Lund and Arantxa Barandiarán Aizpurua and Entela Bollano and Oscar Braun and Jan Leendert P Brouwer and Jan W Buikema and Antonio Cannata and Roy S Gardner and M Louis Handoko and Chim C Lang and Marco Metra and Gianfranco Sinagra and Tonje Thorvaldsen and Robert M A van der Boon and Bart J van Essen and Sanjiv J Shah and Adriaan A Voors and Carolyn S P Lam and Bertram Pitt and Scott D Solomon and Camilla Hage and Marcus Stahlberg and Alberto Bernareggi and Allan Gordon and Marianna Del Sole and Elin Rosendahl and Patrik Stromberg and Goran Westerberg and Robert Edfors and Mark C Petrie},
  year = {2026},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(26)00904-9},
  url = {https://doi.org/10.1016/s0140-6736(26)00904-9}
}

RIS

TY  - JOUR
TI  - Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
AU  - Lars H Lund
AU  - Arantxa Barandiarán Aizpurua
AU  - Entela Bollano
AU  - Oscar Braun
AU  - Jan Leendert P Brouwer
AU  - Jan W Buikema
AU  - Antonio Cannata
AU  - Roy S Gardner
AU  - M Louis Handoko
AU  - Chim C Lang
AU  - Marco Metra
AU  - Gianfranco Sinagra
AU  - Tonje Thorvaldsen
AU  - Robert M A van der Boon
AU  - Bart J van Essen
AU  - Sanjiv J Shah
AU  - Adriaan A Voors
AU  - Carolyn S P Lam
AU  - Bertram Pitt
AU  - Scott D Solomon
AU  - Camilla Hage
AU  - Marcus Stahlberg
AU  - Alberto Bernareggi
AU  - Allan Gordon
AU  - Marianna Del Sole
AU  - Elin Rosendahl
AU  - Patrik Stromberg
AU  - Goran Westerberg
AU  - Robert Edfors
AU  - Mark C Petrie
PY  - 2026
JO  - The Lancet
DO  - 10.1016/s0140-6736(26)00904-9
UR  - https://doi.org/10.1016/s0140-6736(26)00904-9
ER  -

APA

Lund, L. H., Aizpurua, A. B., Bollano, E., Braun, O., Brouwer, J. L. P., Buikema, J. W., Cannata, A., Gardner, R. S., Handoko, M. L., Lang, C. C., Metra, M., Sinagra, G., Thorvaldsen, T., Boon, R. M. A. V. D., Essen, B. J. V., Shah, S. J., Voors, A. A., Lam, C. S. P., Pitt, B., Solomon, S. D., Hage, C., Stahlberg, M., Bernareggi, A., Gordon, A., Sole, M. D., Rosendahl, E., Stromberg, P., Westerberg, G., Edfors, R., & Petrie, M. C. (2026). Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study. The Lancet. https://doi.org/10.1016/s0140-6736(26)00904-9

Source records

crossref · retrieved 2026-09-26T13:51:54.258Z